Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients

BACKGROUND AND OBJECTIVE: Dimethyl fumarate (DMF) is an immunomodulatory drug approved for the therapy of multiple sclerosis (MS). The identification of response biomarkers to DMF is a necessity in the clinical practice. With this aim, we studied the immunophenotypic and transcriptomic changes produ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Sanz, Alicia, García-Martín, Santiago, Sabín-Muñoz, Julia, Moreno-Torres, Irene, Elvira, Víctor, Al-Shahrour, Fátima, García-Grande, Aranzazu, Ramil, Elvira, Rodríguez-De la Fuente, Ofir, Brea-Álvarez, Beatriz, García-Hernández, Ruth, García-Merino, Antonio, Sánchez-López, Antonio José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360655/
https://www.ncbi.nlm.nih.gov/pubmed/37483622
http://dx.doi.org/10.3389/fimmu.2023.1209923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360655/
https://www.ncbi.nlm.nih.gov/pubmed/37483622
http://dx.doi.org/10.3389/fimmu.2023.1209923

Ejemplares similares